Redefining the Concept of Standardization for Pluripotent Stem Cells
- 204 Downloads
In this report we review the concept of standardization and propose an exhaustive framework for the proper management of technology on pluripotent stem cells based on studies of global and regional initiatives. We demonstrated detailed observational analysis on global initiatives for the standardization of related technologies as well as regional attempts with particular interest in the cases of the UK, the US and Japan. Consequently, we came up two fundamental issues: first, these initiatives and attempts tend to be limited to each of currently existing categories of pluripotent stem cells, whereas the technological opportunity to enable clinical/commercial application is equally open to all stem cell types. Second, the subject to be examined for standardization is set to a quite narrow range compared to precedent practices in other industrial sectors. To address these issues, we propose a strategic framework for standardization with an emphasis on comprehensiveness covering various technological opportunities and consistency to learning in the management science. By utilizing this framework development of intellectual property rights not only through patents but through taking leadership in standardization can be considered as means for improving research and development competence. Of particular concerns is the formation of quality standards for final products/services and core elemental technology, especially specific pluripotent stem cell lines. Furthermore, we inferred two stages of the standardization process, individualization where a particular product/service is qualified by the market, then standardization where the elemental technology is subsequently established as compatibility standards.
KeywordsEmbryonic stem cell Induced pluripotent stem cell Intellectual property Regenerative medicine Standardization
We thank Drs. Stephen L. Minger and Chikafumi Yokoyama for their insights and useful advices through interviews. We also thank government officials of Cabinet Secretariat and Ministry of Economy, Trade and Industry of Japan for critical suggestion. The case study was provided under cooperation with ReproCELL, Inc., Yokohama, Japan. This study was supported by World Premier International Research Center (WPI) Initiative from the Ministry of Education, Culture, Sports, Science and Technology of Japan (S. S. and N. N.)
Conflict of Interest
N. N. is a founder of ReproCELL, Inc. The authors report no conflict of interest, particularly no competing financial interest.
- 3.Akopian, V., Andrews, P. W., Beil, S., et al. (2010). Comparison of defined culture systems for feeder cell free propagation of human embryonic stem cells. In Vitro Cellular & Developmental Biology - Animal, 46, 247–258.Google Scholar
- 4.Crook, J. M., Hei, D., Stacey, G. (2010). The International Stem Cell Banking Initiative(ISCBI): raising standards to bank on, In Vitro Cellular and Developmental Biology - Animal, 46, 169–172.Google Scholar
- 5.Wadman, M. (2007). New tools for drug screening. Nature Reports Stem Cells, doi: 10.1038/stemcells.2007.130.
- 6.Nakatsuji, N. (2007). Irrational Japanese regulations hinder human embryonic stem cell research. Nature Reports Stem Cells, doi: 10.1038/stemcells.2007.66.
- 10.Swann, G. M. P. (2000). The economics of standardization: final report for standards and technical regulations directorate. Manchester: University of Manchester Press.Google Scholar
- 15.Asai, Y., Tada, M., Otsuji, G., & Nakatsuji, N. (2010). Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode array system: an ideal hybrid model assay for drug development. Current Stem Cell Research & Therapy, 5(3), 227–232.CrossRefGoogle Scholar